ObjectiveTo explore the efficacy of atorvastatin combined with tirofiban in the treatment of patients with acute coronary syndrome (ACS) combined with arrhythmia, and its influence on the myocardial enzymes and inflammatory factors. MethodsA total of 96 patients with ACS combined with arrhythmia admitted to our hospital from January 2018 to September 2019 were selected, and they were divided into two groups by the random number method, with 48 cases in each group. Both groups of patients were given conventional medicines (atovastatin etc.) and percutaneous coronary intervention (PCI) for treatment, based on which patients in the observation group were additionally treated with tirofiban during and after PCI. The clinical efficacy, the serum myocardial enzymes, and inflammatory factors levels before and after treatment, as well as the occurrence of adverse reactions during the treatment, were compared between the two groups. ResultsAfter 3 months of treatment, the total effective rate of treatment in the observation group (93.8%) was significantly higher than that in the control group (79.2%), and the difference was statistically significant (P＜0.05). The differences of the serum creatine kinase (CK), creatine kinase isoenzyme (CK-MB), high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) levels between the two groups before treatment were not statistically significant (P＞0.05). After 3 months of treatment, the levels of CK, CK-MB, hs-CRP and IL-6 in the observation group were significantly lower than those in the control group, and the differences were statistically significant (P＜0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups during the treatment period (P＞0.05). ConclusionAtorvastatin combined with tirofiban has a definite curative effect in the treatment of patients with ACS combined with arrhythmia, which can effectively inhibit inflammation, alleviate myocardial cell damage, and thus it is highly safe for treatment.

无